人们对目前应用的 2 3价肺炎球菌疫苗的效力是有争议的 ,一些研究证实它不能保护高危患者 ,主要问题是它在 2岁以下儿童及免疫损害患者中的免疫原性较弱。为此作者对一种新型 7价肺炎球菌结合疫苗的免疫原性和耐受性进行了评估。　　作者将受试者分成两组 ,A组为对 2 3价肺炎球 The efficacy of the currently available 2 3 pneumococcal vaccine is controversial. Some studies confirm that it can not protect high-risk patients. The main problem is its weak immunogenicity in children under 2 and immunocompromised patients. To this end the authors evaluated the immunogenicity and tolerability of a novel 7-valent pneumococcal conjugate vaccine. The subjects divided the subjects into two groups, group A for the 23 pneumococcal pneumonia